The advancement of precision psychiatry in treating depressive symptoms provides substantial optimism for
improving treatment outcomes beyond the current status quo. The success of precision psychiatry requires attention to the larger dimensional structure of psychopathology, the expansion of predictive biomarkers, and a mechanistic targeting of specific symptoms or symptom clusters.
The first half of this talk explores how data from novel phenotypic and neuroimaging approaches can inform precision psychiatry of affective disorders. Building on past work on the neural underpinnings of motivation, the second half of the talk examines the potential to capitalize on recent neuropharmacological advances to mechanistically target specific symptoms involving motivational deficits and anergia.